Skip to main content
Toggle navigation
Search
Home
Browse by Poster Title
Home
Browse by Poster Title
Browse by Poster Title
Type here to filter the list
All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
#
Sort by
#
Sort by
Title
P
PI-025
PATIENT PROFILES OF OPIOID USE DISORDER PATIENTS TREATED WITH ORAL VERSUS MONTHLY INJECTABLE BUPRENORPHINE USING U.S. REAL-WORLD MEDICAID CLAIMS DATA.
Favorite
PI-076
PATIENT-CENTRIC MICROSAMPLING VERSUS TRADITIONAL BLOOD SAMPLING: A PHARMACOKINETIC STUDY OF ZAVEGEPANT
Favorite
PII-023
PBPK MODEL DEVELOPMENT AND VALIDATION FOR ROSUVASTATIN: INTEGRATING IN VITRO, CLINICAL PHARMACOKINETIC, AND LIVER PET IMAGING DATA TO IMPROVE PREDICTIONS OF OATP1B- AND BCRP-MEDIATED DRUG-DRUG INTERACTIONS
Favorite
PI-098
PBPK MODEL REPRODUCIBILITY: LEARNINGS FROM THE DEVELOPMENT OF A PBPK MODEL REPOSITORY FOR GLOBAL HEALTH
Favorite
PII-099
PBPK MODELING TO PREDICT THE EFFECT OF GASTRIC PH ON BIOEQUIVALENCE OF PALBOCICLIB TABLETS
Favorite
PII-099
PBPK MODELING TO PREDICT THE EFFECT OF GASTRIC PH ON BIOEQUIVALENCE OF PALBOCICLIB TABLETS
Favorite
PI-099
PBPK MODELING TO SUPPORT THE EXPANSION OF BIOWAIVER TO NON-Q1/Q2 BCS CLASS III DRUG PRODUCTS.
Favorite
PI-113
PBPK-LED ASSESSMENT OF ANTIMALARIAL DRUG CONCENTRATIONS IN BREASTMILK: A STRATEGY FOR OPTIMAL USE OF PREDICTION METHODS TO GUIDE DECISION MAKING IN AN UNDERSTUDIED POPULATION
Favorite
PII-077
PHARMACODYNAMIC MODEL OF CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY IN PATIENTS WITH BREAST CANCER RECEIVING PACLITAXEL
Favorite
PII-006
PHARMACODYNAMIC MODELS AS EARLY PREDICTORS OF WEIGHT LOSS EFFICACY IN EARLY-PHASE CLINICAL RESEARCH
Favorite
PI-077
PHARMACOKINETIC ANALYSIS OF SEVASEMTEN IN A PHASE 1 STUDY IN HEALTHY SUBJECTS AND BECKER MUSCULAR DYSTROPHY PATIENTS
Favorite
PII-078
PHARMACOKINETIC BRIDGING OF JNJ-77242113 ORAL SOLUTION AND TABLET FORMULATIONS.
Favorite
PT-006
PHARMACOKINETIC DRUG-DRUG INTERACTION POTENTIAL OF ORAL ANTICANCER DRUGS.
Favorite
LB-013
PHARMACOKINETIC EVALUATION OF A NATURAL HEMP EXTRACT-BASED COSMETIC PRODUCT AFTER TOPICAL AND ORAL ADMINISTRATIONS.
Favorite
PI-078
PHARMACOKINETIC INTERACTION STUDIES OF COADMINISTRATION OF TAZEMETOSTAT WITH FLUCONAZOLE, REPAGLINIDE, OR OMEPRAZOLE IN PATIENTS WITH ADVANCED MALIGNANCIES.
Favorite
PII-121
PHARMACOKINETICS AND SAFETY OF NANOPARTICLE FENOFIBRATE (AD-104-A) IN RENAL IMPAIRMENT PATIENTS.
Favorite
PII-080
PHARMACOKINETICS OF A FULLY HUMAN BISPECIFIC PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) AND CLUSTER OF DIFFERENTIATION (CD3) BINDING MONOCLONAL ANTIBODY (AMG 340) IN SUBJECTS WITH METASTATIC CASTRATE-RESISTANT PROSTATE CANCER
Favorite
PII-035
PHARMACOKINETICS OF AMG 193 (A SMALL MOLECULE MTA-COOPERATIVE PRMT5 INHIBITOR) AFTER SINGLE AND MULTIPLE DOSING IN THE FASTED AND FED IN STATE PATIENTS WITH MTAP DELETED TUMORS
Favorite
PI-079
PHARMACOKINETICS OF EDG-7500, A FIRST-IN-CLASS CARDIAC SARCOMERE MODULATOR FOR THE TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY
Favorite
PI-080
PHARMACOKINETICS OF NERANDOMILAST IN HEALTHY VOLUNTEERS
Favorite
PI-035
PHARMACOKINETICS OF TARLATAMAB, A DELTA LIKE LIGAND-3 (DLL3) TARGETED HALF-LIFE EXTENDED BISPECIFIC T-CELL ENGAGER (BITE) IMMUNOTHERAPY IN PATIENTS WITH PREVIOUSLY TREATED NEUROENDROCRINE PROSTATE CANCER (NEPC)
Favorite
PII-081
PHARMACOKINETICS OF THB001, AN ORALLY AVAILABLE, POTENT AND HIGHLY SELECTIVE SMALL MOLECULE INHIBITOR OF WILD TYPE KIT RECEPTOR TYROSINE KINASE, IN HEALTHY VOLUNTEERS
Favorite
PI-081
PHARMACOMETRIC MACHINE LEARNING: INTEGRATING NEURAL NETWORKS FOR FLEXIBLE, ADVANCED COVARIATE ANALYSIS
Favorite
PII-113
PHARMACOTHERAPY RESEARCH LANDSCAPE AND KNOWLEDGE GAP FOR OPIOIDS AMONG THE MATERNAL AND PEDIATRIC POPULATIONS
Favorite
PII-010
PHYSICIAN PERCEPTIONS ON ORAL HEALTH FOR PREGNANT WOMEN: BANGLADESH PERSPECTIVE
Favorite
PII-100
PHYSIOLOGICALLY BASED PHARMACOKINETIC (PBPK) MODELLING FOR PREDICTING DRUG-DRUG INTERACTIONS (DDI) OF SHR2554
Favorite
PI-100
PHYSIOLOGICALLY-BASED PHARMACOKINETIC (PBPK) MODELING TO CHARACTERIZE THE DISPOSITION OF TOPIRAMATE IN CHILDREN WITH AND WITHOUT OBESITY USING REAL-WORLD DATA.
Favorite
PII-101
PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODEL ANALYSIS OF ANTIPSYCHOTICS BEFORE AND AFTER CHILDBIRTH.
Favorite
TIP-003
PILOT STUDY ON VANCOMYCIN ADMINISTRATION VIA DIALYSATE IN PATIENTS RECEIVING CONTINUOUS RENAL REPLACEMENT THERAPY (CRRT)
Favorite
TIP-003
PILOT STUDY ON VANCOMYCIN ADMINISTRATION VIA DIALYSATE IN PATIENTS RECEIVING CONTINUOUS RENAL REPLACEMENT THERAPY (CRRT)
Favorite
PII-082
POPULATION EXPOSURE-RESPONSE ANALYSIS OF INOTUZUMAB OZOGAMICIN EFFICACY AND SAFETY IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA.
Favorite
PI-082
POPULATION PHARMACOKINETIC (PK)-PHARMACODYNAMIC (PD) MODELING OF ANUMIGILIMAB, A MONOCLONAL ANTIBODY THAT BLOCKS G-CSF BINDING TO THE G-CSF RECEPTOR
Favorite
PII-083
POPULATION PHARMACOKINETIC (POPPK) MODELING OF ENCORAFENIB (ENCO) IN HEALTHY PARTICIPANTS AND PARTICIPANTS WITH BRAF V600-MUTANT SOLID TUMORS IN PHASE 1, 2, AND 3 STUDIES: A SEMIMECHANISTIC AUTOINDUCTION MODEL.
Favorite
PI-083
POPULATION PHARMACOKINETIC ANALYSIS OF DUVAKITUG (TEV-48574) IN HEALTHY PARTICIPANTS AND PATIENTS WITH ASTHMA.
Favorite
PII-084
POPULATION PHARMACOKINETIC ANALYSIS OF MK-5475 IN HEALTHY PARTICIPANTS AND PATIENTS WITH PULMONARY HYPERTENSION
Favorite
PI-084
POPULATION PHARMACOKINETIC ANALYSIS OF SOTATERCEPT IN JAPANESE HEALTHY PARTICIPANTS AND JAPANESE PARTICIPANTS WITH PULMONARY ARTERIAL HYPERTENSION.
Favorite
PI-114
POPULATION PHARMACOKINETIC ANALYSIS TO OPTIMIZE THE DOSING REGIMEN OF 17-OHPC FOR PREVENTION OF PRETERM BIRTH
Favorite
PII-085
POPULATION PHARMACOKINETIC AND EXPOSURE-RESPONSE ANALYSIS OF ABATACEPT IN COVID-19 PATIENTS
Favorite
PI-085
POPULATION PHARMACOKINETIC MODEL OF TOTAL AND UNBOUND PAMIPARIB, A PARP INHIBITOR, IN GLIOBLASTOMA PATIENTS
Favorite
PII-086
POPULATION PHARMACOKINETIC MODELING OF FAMITINIB IN PATIENTS WITH VARIOUS CANCER TYPES INCLUDING METASTATIC CERVICAL CANCER
Favorite
PI-036
POPULATION PHARMACOKINETIC MODELING OF SUNITINIB AND SU12662 IN PATIENTS WITH SOLID TUMORS
Favorite
PI-086
POPULATION PHARMACOKINETIC OF BMS-986365, A DUAL ANDROGEN RECEPTOR (AR) LIGAND-DIRECTED DEGRADER AND ANTAGONIST, IN PATIENTS WITH PROGRESSIVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Favorite
PII-087
POPULATION PHARMACOKINETIC/PHARMACODYNAMIC (PK/PD) MODELING OF DONIDALORSEN, AN ANTISENSE OLIGONUCLEOTIDE IN DEVELOPMENT FOR PROPHYLAXIS OF HEREDITARY ANGIOEDEMA.
Favorite
LB-014
POPULATION PHARMACOKINETICS AND BIOAVAILABILITY OF TACROLIMUS ORAL SUSPENSION IN CHILDREN WITH HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT)
Favorite
PI-087
POPULATION PHARMACOKINETICS AND EXPOSURE-RESPONSE ANALYSIS FOR NTLA-2002 IN PATIENTS WITH HEREDITARY ANGIOEDEMA
Favorite
PII-088
POPULATION PHARMACOKINETICS AND EXPOSURE-RESPONSE ANALYSIS FOR THE BIFUNCTIONAL PD-L1/TGF-βRII FUSION PROTEIN RETLIRAFUSP ALPHA TO SUPPORT A FLAT DOSE AS AN ALTERNATIVE REGIMEN
Favorite
PII-019
POPULATION PHARMACOKINETICS OF DELAMANID AND ITS METABOLITE DM-6705 IN MULTIDRUG-RESISTANT TUBERCULOSIS PATIENTS RECEIVING NOVEL SHORT-COURSE ORAL REGIMENS IN THE ENDTB AND ENDTB-Q TRIALS
Favorite
PI-088
POPULATION PHARMACOKINETICS OF ELEXACAFTOR, TEZACAFTOR AND IVACAFTOR IN REAL WORLD ADULT PATIENTS WITH CYSTIC FIBROSIS
Favorite
PII-089
POPULATION PHARMACOKINETICS OF ORAL MELTDOSE TACROLIMUS (LCPT) IN DE NOVO KIDNEY TRANSPLANT PATIENTS.
Favorite
PI-089
POPULATION PHARMACOKINETICS OF PYRAZINAMIDE FOR PATIENTS WITH MULTIDRUG RESISTANT TUBERCULOSIS
Favorite
LB-015
POPULATION PHARMACOKINETICS OF THE PARP INHIBITOR VELIPARIB IN PATIENTS WITH ADVANCED CANCER.
Favorite
PII-001
POPULATION PHARMACOKINETICS OF TRASTUZUMAB REZETECAN IN PATIENTS WITH HER2 EXPRESSING OR MUTATED ADVANCED MALIGNANT SOLID TUMORS
Favorite
PII-090
POPULATION PK (POPPK) AND EXPOSURE-SAFETY (E-S) ANALYSIS OF BT5528, A BICYCLE TOXIN CONJUGATE (BTC®), IN PATIENTS WITH ADVANCED SOLID TUMORS ASSOCIATED WITH EPHA2 EXPRESSION.
Favorite
PII-106
POPULATION PK AND PK/PD MODELING OF MARSTACIMAB, AN ANTI-TFPI MONOCLONAL ANTIBODY, IN ADULT AND ADOLESCENT HEMOPHILIA PATIENTS WITHOUT INHIBITORS
Favorite
PII-106
POPULATION PK AND PK/PD MODELING OF MARSTACIMAB, AN ANTI-TFPI MONOCLONAL ANTIBODY, IN ADULT AND ADOLESCENT HEMOPHILIA PATIENTS WITHOUT INHIBITORS
Favorite
PII-052
PRECISION MEDICINE IN PRACTICE: DEVELOPMENT OF AN AUTOMATED WARFARIN PHARMACOGENOMIC DOSING CALCULATOR EMBEDDED IN THE ELECTRONIC HEALTH RECORD.
Favorite
PII-036
PRECLINICAL TO CLINICAL TRANSLATION OF ADVERSE EVENTS FOR SMALL MOLECULE ONCOLOGY DRUGS
Favorite
PI-101
PREDICTING BRINZOLAMIDE OCULAR RESPONSE IN HUMANS USING AN OCULAR PBPK-PD MODELING AND SIMULATION
Favorite
PI-101
PREDICTING BRINZOLAMIDE OCULAR RESPONSE IN HUMANS USING AN OCULAR PBPK-PD MODELING AND SIMULATION
Favorite
PI-020
PREDICTING OPTIMAL PATIENT-CENTRIC TREATMENT DURATION FOR LEVOFLOXACIN-CONTAINING TUBERCULOSIS REGIMEN: AN INTEGRATED APPROACH OF A MODEL-BASED STRATIFICATION TOOL WITH SITE-OF-DISEASE PHARMACOLOGY KNOWLEDGE
Favorite
PII-102
PREDICTING THE EXPOSURE OF IRINOTECAN AND ITS ACTIVE METABOLITE (SN-38) IN CANCER PATIENTS USING PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELING.
Favorite
PI-102
PREDICTION OF A CLAUDIN 18.2 TARGETED ANTIBODY DRUG CONJUGATE (ADC) PHARMACOKINETICS IN CANCER PATIENTS USING PBPK MODELING AND SIMULATION
Favorite
PII-124
PREDICTION OF CLINICAL OUTCOMES IN A HETEROGENOUS NSCLC VIRTUAL PATIENT POPULATION: A QUANTITATIVE SYSTEMS PHARMACOLOGY APPROACH.
Favorite
PI-024
PROMISING CAPACITY OF MACHINE LEARNING MODELS TO PREDICT OATP1B1- AND OATP1B3-MEDIATED INHIBITION POTENTIAL IN EARLY DRUG DISCOVERY.
Favorite
PI-090
PROTEIN BINDING: STATIC SOLUTIONS TO A DYNAMIC PROBLEM CAN BE MISLEADING IN DRUG DEVELOPMENT AND REGULATORY EVALUATION.
Favorite
PI-007
PROTEOMIC SIGNATURES IN THE CEREBROSPINAL FLUID (CSF) OF INDIVIDUALS WITH PRECLINICAL AND PRODROMAL ALZHEIMER'S DISEASE (AD): A KEY ROLE FOR ENDOTHELIAL AND ADHESION PROTEINS IN PRECLINICAL AD.
Favorite
PII-007
PYRIDOXIC ACID AS ENDOGENOUS BIOMARKER OF RENAL ORGANIC ANION TRANSPORTER ACTIVITY: POPULATION VARIABILITY AND MECHANISTIC MODELING TO PREDICT DRUG-DRUG INTERACTIONS
Favorite
